{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T21:48:54Z","timestamp":1791236934130,"version":"4.1.0"},"reference-count":13,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.clinthera.2014.07.004","type":"journal-article","created":{"date-parts":[[2014,8,3]],"date-time":"2014-08-03T00:45:16Z","timestamp":1407026716000},"page":"1412-1421","source":"Crossref","is-referenced-by-count":16,"title":["Efficacy and Safety of 30-Mg Fimasartan for the Treatment of Patients With Mild to Moderate Hypertension: An 8-Week, Multicenter, Randomized, Double-Blind, Phase III Clinical Study"],"prefix":"10.1016","volume":"36","clinical-trial-number":[{"clinical-trial-number":"nct01672476","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Jong-Chan","family":"Youn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-Hyun","family":"Ihm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jang-Ho","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seong-Mi","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Woon","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byung-Chun","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae Ho","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nae Hee","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong-Min","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Won","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Seok","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ki Chul","family":"Sung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In Hyun","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wook Bum","family":"Pyun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung-Jae","family":"Joo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woo Jung","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Ho","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seok-Min","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2014.07.004_bib1","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1248\/bpb.b12-00966","article-title":"Pharmacological characterization of BR-A-657, a highly potent nonpeptide angiotensin II receptor antagonist","volume":"36","author":"Chi","year":"2013","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.clinthera.2014.07.004_bib2","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1097\/FJC.0b013e31822b9092","article-title":"The effect of the newly developed angiotensin receptor II antagonist fimasartan on the pharmacokinetics of atorvastatin in relation to OATP1B1 in healthy male volunteers","volume":"58","author":"Shin","year":"2011","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.clinthera.2014.07.004_bib3","doi-asserted-by":"crossref","first-page":"335","DOI":"10.2165\/11593840-000000000-00000","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of fimasartan following single and repeated oral administration in the fasted and fed states in healthy subjects","volume":"11","author":"Chi","year":"2011","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.clinthera.2014.07.004_bib4","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/j.clinthera.2012.04.021","article-title":"Efficacy and tolerability of once-daily oral fimasartan 20 to 240 mg\/d in Korean patients with hypertension: findings from two Phase II, randomized, double-blind, placebo-controlled studies","volume":"34","author":"Lee","year":"2012","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2014.07.004_bib5","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/j.clinthera.2013.06.021","article-title":"Ambulatory blood pressure response to once-daily fimasartan: an 8-week, multicenter, randomized, double-blind, active-comparator, parallel-group study in Korean patients with mild to moderate essential hypertension","volume":"35","author":"Lee","year":"2013","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2014.07.004_bib6","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.clinthera.2012.01.024","volume":"34","author":"Lee","year":"2012","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2014.07.004_bib7","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1472-8206.2007.00464.x","article-title":"Blood pressure-lowering efficacy of olmesartan relative to other angiotensin II receptor antagonists: an overview of randomized controlled studies","volume":"21","author":"Zannad","year":"2007","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2014.07.004_bib8","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1161\/HYPERTENSIONAHA.110.163402","article-title":"Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension","volume":"57","author":"White","year":"2011","journal-title":"Hypertension"},{"key":"10.1016\/j.clinthera.2014.07.004_bib9","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1097\/FJC.0b013e31821795d0","article-title":"Pharmacokinetic interaction of fimasartan, a new angiotensin II receptor antagonist, with amlodipine in healthy volunteers","volume":"57","author":"Yi","year":"2011","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.clinthera.2014.07.004_bib10","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/sj.jhh.1000925","article-title":"ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension","volume":"13","author":"Mallion","year":"1999","journal-title":"J Hum Hypertens"},{"key":"10.1016\/j.clinthera.2014.07.004_bib11","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/S0149-2918(98)80051-9","article-title":"An elective-titration study of the comparative effectiveness of two angiotensin II-receptor blockers, irbesartan and losartan. Irbesartan\/Losartan Study Investigators","volume":"20","author":"Oparil","year":"1998","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2014.07.004_bib12","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S0895-7061(97)00491-3","article-title":"Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan in mild-to-moderate hypertension. Irbesartan\/Losartan Study Investigators","volume":"11","author":"Kassler-Taub","year":"1998","journal-title":"Am J Hypertens"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2014.07.004_bib13","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1038\/sj.jhh.1000991","article-title":"Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension","volume":"14","author":"Israili","year":"2000","journal-title":"J Hum Hypertens"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291814004391?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291814004391?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T05:34:15Z","timestamp":1538372055000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291814004391"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":13,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["S0149291814004391"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2014.07.004","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]}}}